KAT6 catalysts to kick off 2025
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
ImmunityBio follows through in lung cancer
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
FDA red and green lights: December 2024
Subcutaneous Opdivo joins Tecentriq Hybreza to round out 2024.
Ideaya's conjugate journey continues
The synthetic lethality specialist licenses in its second ADC in six months.
Braftovi outdoes Tafinlar in colorectal cancer
US approval gives Pfizer the first and second-line settings.
